may 17, 2018 -- the fda has approved the first in a new class of migraine drugs that aim to fight painful.
the state launched a review into the newspaper�s findings in late april.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance..